Table 1.
Baseline characteristics
| Variables | Sedentary group (n = 31) | Active group (n = 28) |
P value |
|---|---|---|---|
| Age (years), mean ± SD | 55.9 ± 12.4 | 53.5 ± 8.1 | 0.387 |
| Gender | |||
| Male | 26 (83.9%) | 27 (96.4%) | 0.245 |
| Female | 5 (16.1%) | 1 (3.6%) | |
| PS score | |||
| 0 | 12 (38.7%) | 18 (64.3%) | 0.050 |
| 1 | 19 (61.3%) | 10 (35.7%) | |
| Overweight | |||
| No | 30 (96.8%) | 26 (92.9%) | 0.599 |
| Yes | 1 (3.2%) | 2 (7.1%) | |
| Child–Pugh classification | |||
| A | 30 (96.8%) | 27 (96.4%) | 1.000 |
| B | 1 (3.2%) | 1 (3.6%) | |
| BCLC stage | |||
| A | 1 (3.2%) | 3 (10.7%) | 0.520 |
| B | 7 (22.6%) | 6 (21.4%) | |
| C | 23 (74.2%) | 19 (67.9%) | |
| CNLC stage | |||
| I | 1 (3.2%) | 3 (10.7%) | 0.520 |
| II | 7 (22.6%) | 6 (21.4%) | |
| III | 23 (74.2%) | 19 (67.9%) | |
| Tumor size (cm), mean ± SD | 12.3 ± 5.5 | 10.7 ± 5.8 | 0.351 |
| Extra-hepatic metastasis | |||
| No | 26 (83.9%) | 21 (75.0%) | 0.398 |
| Yes | 5 (16.1%) | 7 (25.0%) | |
| Macrovascular invasion | |||
| No | 11 (35.5%) | 14 (50.0%) | 0.260 |
| Yes | 20 (64.5%) | 14 (50.0%) | |
| WBC (× 109/L), mean ± SD | 5.8 ± 2.0 | 5.7 ± 1.9 | 0.828 |
| NLR, mean ± SD | 3.3 ± 1.6 | 2.7 ± 1.2 | 0.124 |
| TB (μmol/L), mean ± SD | 17.5 ± 9.6 | 16.7 ± 7.6 | 0.753 |
| ALB (g/L), mean ± SD | 38.5 ± 5.8 | 41.6 ± 4.0 | 0.020 |
| ALT (U/L), mean ± SD | 42.0 ± 26.3 | 40.8 ± 24.7 | 0.856 |
| AST (U/L), mean ± SD | 73.7 ± 68.4 | 51.6 ± 34.8 | 0.130 |
| GGT (U/L), mean ± SD | 234.9 ± 223.9 | 183.3 ± 211.8 | 0.368 |
| INR, mean ± SD | 1.2 ± 0.1 | 1.1 ± 0.1 | 0.092 |
| AFP (ng/mL) | |||
| < 400 | 13 (41.9%) | 11 (39.3%) | 0.836 |
| ≥ 400 | 18 (58.1%) | 17 (60.7%) | |
| DCP (mAU/mL) | |||
| < 400 | 3 (9.70%) | 10 (35.7%) | 0.036 |
| ≥ 400 | 28 (90.3%) | 18 (64.3%) | |
| HBsAg | |||
| – | 05 (16.1%) | 6 (21.4%) | 0.602 |
| + | 26 (83.9%) | 22 (78.6%) | |
| Antiviral therapies | |||
| Entecavir | 22 (84.6%) | 18 (81.8%) | 0.796 |
| Tenofovir disoproxil fumarate | 4 (15.4%) | 4 (18.2%) | |
| HBV-DNA (IU/mL) | |||
| ≤ 1000 | 13 (41.9%) | 21 (75.0%) | 0.010 |
| > 1000 | 18 (58.1%) | 7 (25.0%) | |
AFP alpha-fetoprotein ,ALB albumin, ALT alanine transaminase, AST aspartate transaminase, BCLC Barcelona Clinic Liver Cancer, CNLC China Liver Cancer, DCP des-γ-carboxy prothrombin, GGT gamma-glutamyl transpeptidase, HBV hepatitis B virus, HbsAg hepatitis B surface antigen, INR international normalized ratio, NLR neutrophil–lymphocyte ratio, PS performance status, TB total bilirubin, WBC white blood count